Prevention of Diabetic Nephropathy by Sulforaphane: Possible Role of Nrf2 Upregulation and Activation

Table 1

Effects of SFN on blood glucose and renal function in diabetic mice.

	3 months			6 months
	BG (mmol/L)	KW/TL (mg/mm)	ACR (𝜇g/mg)	BG (mmol/L)	KW/TL (mg/mm)	ACR (𝜇g/mg)
Control	120.3 ± 13.6	24.9 ± 2.0	101.5 ± 8.0	121.0 ± 9.9	27.9 ± 2.3	127.0 ± 13.4
SFN	115.7 ± 19.9	22.1 ± 2.5	111.3 ± 13.9	116.3 ± 10.5	27.4 ± 2.5	136.1 ± 17.6
DM	413.3 ± 23.6*	42.9 ± 2.2*	542.0 ± 96.9*	282.7 ± 10.5*	47.5 ± 3.2*	1009.6 ± 225.8*
DM/SFN	419.7 ± 29.4*	35.5 ± 3.0^*#	375.9 ± 62.7^*#	347.5 ± 20.2*	46.6 ± 3.1*	1071.2 ± 301.8*

Notes: Data were presented as means ± SD. *P < 0.05 versus control; ^#P < 0.05 versus DM group. SFN: sulforaphane; DM: diabetes mellitus; BG: blood glucose; KW/TL: kidney weight to tibia length ratio; ACR: albumin-to-creatinine ratio.